1.Suwannakarn, K, et al. Molecular evolution of human H1N1 and H3N2 influenza A virus in Thailand, 2006–2009. PLoS One 2010; 5: e9717.
2.Lavenu, A, et al. Detailed analysis of the genetic evolution of influenza virus during the course of an epidemic. Epidemiology and Infection 2006; 134: 514–520.
3.Dawood, FS, et al. Emergence of a novel swine-origin influenza A (H1N1) virus in humans. New England Journal of Medicine 2009; 360: 2605–2615.
4.Huang, P, et al. Influenza. Guangzhou: Guangdong Technological Press 2004, pp. 89–91.
5.Skehel, JJ, et al. Influenza haemagglutinin. Vaccine 2002; 20 (Suppl. 2): S51–54.
6.Huang, IC, et al. Influenza A virus neuraminidase limits viral superinfection. Journal of Virology 2008; 82: 4834–4843.
7.Huang, P, et al. Molecular evolution of Guangdong influenza virus isolates in influenza outbreak in 1996. Virologica Sinica 2001; 16: 1–5.
8.Saitoh, M, et al. Molecular evolution of HA1 in influenza A (H3N2) viruses isolated in Japan from 1989 to 2006. Intervirology 2008; 51: 377–384.
9.Hurt, AC, et al. Oseltamivir-resistant influenza viruses circulating during the first year of the influenza A(H1N1)2009 pandemic in the Asia-Pacific region, March 2009 to March 2010. Eurosurveillance 2011; 16: pii=19770.
10.Wu, W, et al. Clusters of spatial, temporal, and space-time distribution of hemorrhagic fever with renal syndrome in Liaoning Province, Northeastern China. BMC Infectious Diseases 2011; 11: 229.
11.Blair, PJ, et al. Influenza epidemiology and characterization of influenza viruses in patients seeking treatment for acute fever in Cambodia. Epidemiology and Infection 2010; 138: 199–209.
12.Tamura, K, et al. MEGA5: Molecular Evolutionary Genetics Analysis using maximum likelihood, evolutionary distance, and maximum parsimony methods. Molecular Biology and Evolution 2011; 28: 2731–2739.
13.Baek, YH, et al. Molecular characterization and phylogenetic analysis of H3N2 human influenza A viruses in Cheongju, South Korea. Journal of Microbiology 2009; 47: 91–100.
14.Sheu, TG, et al. Surveillance for neuraminidase inhibitor resistance among human influenza A and B viruses circulating worldwide from 2004 to 2008. Antimicrobial Agents and Chemotherapy 2008; 52: 3284–3892.
15.Yen, HL, et al. Importance of neuraminidase active-Site residues to the neuraminidase inhibitor resistance of influenza viruses. Journal of Virology 2006; 80: 8787–8795.
16.Ding, X, et al. Amino acid sequence analysis and identification of mutations under positive selection in hemagglutinin of 2009 influenza A (H1N1) isolates. Virus Genes 2010; 41: 329–340.
17.Wile, DC, et al. Structural dentification of the antibody-binding sites of Hong Kong influenza hemagglutinin and their involvement in antigentic variation. Nature 1981; 289: 373–378.
18.Weis, W, et al. Structure of the influenza virus hemagglutinin complexed with its receptor, sialic acid. Nature 1998; 333: 426–431.
19.Colman, PM, et al. Structure of the catalytic and antigenic sites in influenza virus neuraminidase. Nature 1983; 303: 41–44.
20.Liang, L, et al. Epitope peptides of influenza H3N2 neuraminidase gene designed by immunoinformatics. Acta Biochimica et Biophysica Sinica 2012; 44: 113–118.
21.Zhong, J, et al. Antigenic epitope peptides of influenza H3N2 virus neuraminidase gene based on experiments. Chinese Science Bulletin 2012; 57: 2908–2913.
22.Huang, JW, et al. Changed epitopes drive the antigenic drift for influenza A (H3N2) viruses. BMC Bioinformatics 2011; 12 (Suppl. 1): S31.
23.Pan, K, et al. Selective pressure to increase charge in immuno-dominant epitopes of the H3 hemagglutinin influenza protein. Journal of Molecular Evolution 2011; 72: 90–103.
24.Arinaminpathy, N, et al. Dynamics of Glycoprotein Charge in the Evolutionary History of Human Influenza. PLos One 2011; 5: e15674.
25.Centers for Disease Control and Prevention. Prevention and control of influenza with vaccines: recommendations of the advisory committee on immunization practices (ACIP), 2011. Morbidity and Mortality Weekly Report 2011; 60: 1128–1132.